FIELD: medicine.
SUBSTANCE: invention relates to therapy and pulmonology, and can be used to predict the incidence of exacerbations of chronic obstructive pulmonary disease (COPD) based on blood plasma laboratory values. Level of C-reactive protein and fractalkine is determined by enzyme immunoassay combined with establishing the COPD phenotype: emphysematous, mixed, bronchitic or phenotype of bronchial asthma with COPD (BA + COPD), presence of pneumococcal vaccination. Probability of frequent exacerbations of COPD is calculated by formula
where p is the probability of frequent exacerbations of COPD - 2–3 times a year in fractions of a unit; e is Euler's number (constant) equal to 2.71828; z = −3.434 + 0.501 × CRP + 2.389 × Emph PH + 2.311×C×Br PH−4.395×CX3CL1−2.927×PV; where −3.434 is a constant; 0.501 is the coefficient of the first variable; CRP is the level of C-reactive protein, mg/l; in case of BA + COPD phenotype in patient: Emph PH is equal to 0, Mix PH is equal to 0, Br PH is equal to 0; 2.389 is the coefficient of the second variable; Emph PH is emphysematous phenotype of COPD, in case of presence of this phenotype in patient: Emph PH is equal to 1, Mix PH is equal to 0, Br PH is equal to 0; 2.311 is the coefficient of the third variable; Mix PH is mixed COPD phenotype, if the patient has this phenotype: Mix PH is equal to 1, Emph PH is equal to 0, Br PH is equal to 0; 3.663 is the coefficient of the fourth variable; Br PH is bronchitic phenotype of COPD, in case of presence of this phenotype in patient: Br PH is equal to 1, Emph PH is equal to 0, Mix PH is equal to 0; −4.395 is the coefficient of the fifth variable; CX3CL1 is fractalkine level, ng/ml; −2.927 is the coefficient of the sixth variable; PV - pneumococcal vaccination: 0 – absence, 1 – presence. If p is less than 0.5, a low risk of frequent exacerbations of COPD is predicted. If p is more than or equal to 0.5, a high risk of frequent exacerbations of COPD is predicted.
EFFECT: method enables to predict the rate of development of exacerbations in patients with different phenotypes of COPD due to: determining blood C-reactive protein and fractalkine, establishing the COPD phenotype and the presence of pneumococcal vaccination.
1 cl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF RISK OF DEVELOPING LIFE THREATENING COMPLICATIONS IN PATIENTS WITH MYOCARDIAL INFARCTION WITH BACKGROUND OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2019 |
|
RU2740896C1 |
METHOD FOR PREDICTION OF EFFECTIVE TREATMENT WITH ROFLUMILAST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHENOTYPE "WITH FREQUENT EXACERBATIONS" | 2019 |
|
RU2712244C1 |
METHOD OF ACTIVATING FACTORS OF ANTIVIRAL PROTECTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015 |
|
RU2591809C1 |
METHOD FOR FORMING IMMUNOLOGICAL MEMORY TO STREPTOCOCCUS PNEUMONIAE ANTIGENS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2014 |
|
RU2544168C1 |
METHOD FOR PREDICTING RISK OF DEVELOPMENT OF ISCHEMIC HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015 |
|
RU2620545C1 |
METHOD FOR PREDICTING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PERSONS WORKING UNDER EXPOSURE TO INDUSTRIAL AEROSOLS | 2021 |
|
RU2774206C1 |
METHOD FOR PREDICTION EFFICACY OF GLUCOCORTICOID THERAPY IN PATIENTS WITH AGGRAVATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2011 |
|
RU2490645C2 |
METHOD OF ENHANCING NONSPECIFIC PROTECTION FACTORS ACTIVITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015 |
|
RU2600838C1 |
METHOD FOR PREDICTING RECRUDESCENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS WITH INSOMNIA | 2018 |
|
RU2681272C1 |
METHOD FOR PREDICTING THE FREQUENCY OF EXACERBATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2016 |
|
RU2657788C1 |
Authors
Dates
2024-07-01—Published
2023-04-04—Filed